Early clinical results deliver encouraging milestone for malaria drug candidate

Findings from two early clinical studies suggest a new dual-action antimalarial drug candidate is well tolerated in humans. The first-in-class clinical candidate, MK7602, is being developed by WEHI and global biopharmaceutical company MSD…

Continue Reading

News Source: medicalxpress.com